An Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Lipegfilgrastim 100 μg/kg Body Weight in Comparison to Filgrastim 5 μg/kg Body Weight in Pediatric Patients Diagnosed with Ewing Family of Tumors or Rhabdomyosarcoma Receiving Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Lipegfilgrastim (Primary) ; Filgrastim
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Merckle
- 19 Jan 2018 This trial has been completed in Poland.
- 10 Jun 2017 This trial has been suspended in Spain.
- 18 Jun 2015 New trial record